An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Appili Therapeutics has appointed Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program.
Dr. Gelhaus brings over 20 years of expertise in infectious disease research, specifically on Francisella tularensis, while Baran has more than 22 years of experience in drug development and business operations.
The appointments come at a crucial time following recent funding from DTRA for the ATI-1701 program, aimed at developing a vaccine to combat serious biological threats.
Positive
Dr. Gelhaus and Mr. Baran bring extensive expertise that could enhance the ATI-1701 project's development.
Recent funding from DTRA supports the advancement of the ATI-1701 program.
Negative
Concerns may arise regarding continuity and experience gaps within the leadership team as new roles are filled.
Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Francisella tularensis, which is classified by the U.S. National Institutes of Health as a Category A pathogen and top-priority biothreat.
Dr. Gelhaus brings over 20 years of infectious disease and animal model research experience to the role, with an emphasis on tularemia research. Carl has a long history as a research partner with Appili on ATI-1701, including having designed and conducted key animal model efficacy studies for ATI-1701. Carl also presented the positive interim data in January 2020 at the 2020 ASM Biothreats Conference . At Appili, Carl will recruit and lead the research and development team of Ph.D. and non-Ph.D. scientists, design and manage pre-clinical studies, and manage contract research organizations to support pre-clinical development programs.
Arthur Baran brings to Appili more than 22 years of experience in global product manufacturing operations, drug product development team leadership, program management, business development, manufacturing site leadership and quality assurance. Art will focus his work at Appili on building systems, processes, and tools to facilitate business planning and decision-making, as well as streamlining product leadership and management capabilities within Appili.
“We are fortunate to have both Carl and Arthur join our team at a pivotal time in Appili’s development and growth. With our recent funding from DTRA for the ATI-1701 program, both Carl’s expertise with Francisella tularensis and Art’s skills in program management and internal organization will be valuable to us as we move ATI-1701 forward,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics.
About Appili Therapeutics
Appili Therapeutics is an infectious disease and biodefense biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
Forward-Looking Statements
This news release contains “forward-looking statements”, including with respect to the Company’s ongoing development plans and timeline with respect to ATI-1701. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for,” and similar expressions have been used to identify these forward-looking statements.
Forward looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the risk factors listed in the annual information form of the Company dated June 23, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.
What is the significance of the new appointments at Appili Therapeutics?
The appointments of Dr. Gelhaus and Mr. Baran are crucial for advancing the ATI-1701 program, particularly in developing a vaccine against Francisella tularensis, which is a high-priority biothreat.
Who are the new directors appointed at Appili Therapeutics?
Dr. Carl Gelhaus is appointed as Director of Non-Clinical Research, and Arthur Baran is the new Director of New Product Development.
What is the ATI-1701 program focused on?
The ATI-1701 program is focused on developing a first-in-class vaccine candidate for preventing infections caused by aerosolized Francisella tularensis.
How might the leadership changes impact Appili Therapeutics?
The leadership changes could bring new perspectives and expertise to the company, potentially accelerating the development of critical biopharmaceutical products.
